Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy
Clinical Trials
Related News

Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

First Posted Date
2021-02-04
Last Posted Date
2023-05-18
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
30
Registration Number
NCT04737889
Locations
🇨🇳

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

First Posted Date
2021-01-25
Last Posted Date
2024-10-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
140
Registration Number
NCT04722146
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Weill Cornell Medical College, New York, New York, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 24 locations

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

First Posted Date
2021-01-15
Last Posted Date
2024-11-26
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
474
Registration Number
NCT04712097
Locations
🇦🇺

Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia

🇫🇷

Institut Paoli Calmettes, Marseille, France

🇩🇪

Medizinische Klinik IV, Hämatologie Universitätsklinikum Gießen, Giessen, Germany

and more 150 locations

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

First Posted Date
2020-12-22
Last Posted Date
2024-08-15
Lead Sponsor
Incyte Corporation
Target Recruit Count
654
Registration Number
NCT04680052
Locations
🇺🇸

John Muir Health Clinical Research Center, Concord, California, United States

🇺🇸

Metro-Minnesota Community Oncology Reserch Consortium (Mmcorc), Saint Louis Park, Minnesota, United States

🇺🇸

Hattiesburg Clinic Hematology, Hattiesburg, Mississippi, United States

and more 256 locations

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

First Posted Date
2020-12-16
Last Posted Date
2024-12-13
Lead Sponsor
Enterome
Target Recruit Count
60
Registration Number
NCT04669171
Locations
🇫🇷

CHU d'Amiens-Picardie - Hopital SUD, Amiens, France

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

and more 7 locations

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

First Posted Date
2020-12-11
Last Posted Date
2024-12-11
Lead Sponsor
Genmab
Target Recruit Count
543
Registration Number
NCT04663347
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

and more 55 locations

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

First Posted Date
2020-12-09
Last Posted Date
2024-12-10
Lead Sponsor
Incyte Biosciences Japan GK
Target Recruit Count
65
Registration Number
NCT04661007
Locations
🇯🇵

Aichi Cancer Center Hospital, Aichi, Japan

🇯🇵

Chiba Cancer Center, Chiba, Japan

🇯🇵

National Cancer Center Hospital East, Chiba, Japan

and more 20 locations

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

First Posted Date
2020-12-04
Last Posted Date
2024-11-12
Lead Sponsor
Jacob Laubach, MD
Target Recruit Count
52
Registration Number
NCT04653246
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

First Posted Date
2020-11-19
Last Posted Date
2022-09-30
Lead Sponsor
Yazeed Sawalha
Registration Number
NCT04635683

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

Phase 2
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Drug: Daratumumab
Drug: Lenalidomide
Drug: Dexamethasone
First Posted Date
2020-11-19
Last Posted Date
2024-07-09
Lead Sponsor
University of Rochester
Target Recruit Count
28
Registration Number
NCT04635189
Locations
🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy